• Home
  • Find a Pharmacy
  • Health News
  • Medications
  • Conditions
  • RxCoupons
  • Pharmacy Solutions
RxWiki - Home
Find a Pharmacy Health News Medications Conditions RxCoupons Pharmacy Solutions

Health News

Revlimid and Risk of New Cancers
The U.S. Food and Drug Administration (FDA) is informing the public of an increased risk of second primary malignancies (new types of cancer) in patients with newly-diagnosed multiple myeloma who received Revlimid ( lenalidomide ).
FDA Drug Safety Communication: Adcetris (brentuximab vedotin)
The U.S. Food and Drug Administration (FDA) is notifying the public that two additional cases of progressive multifocal leukoencephalopathy ( PML ), a rare but serious brain infection that can result in death, have been reported with the lymphoma drug Adcetris ( brentuximab vedotin ).
FDA Warning: Breast Implants Linked to Rare Cancer
The U.S. Food and Drug Administration today announced a possible association between saline and silicone gel-filled breast implants and anaplastic large cell lymphoma ( ALCL ), a very rare type of cancer.

REFINE

  • medications
      • Revlimid (1) Apply Revlimid filter
  • conditions
      • (-) Remove Hematology filter Hematology
        • (-) Remove Blood Cancer filter Blood Cancer
          • (-) Remove Lymphoma filter Lymphoma
          • Leukemia (1) Apply Leukemia filter
          • Multiple Myeloma (1) Apply Multiple Myeloma filter
      • (-) Remove Patient Safety Education filter Patient Safety Education
      • Cancer (2) Apply Cancer filter
All information on this site is provided "as-is" for informational purposes only and is not a substitute for medical advice or treatment. You should consult with a medical professional if you have any questions about your health. The use of any information on this site is solely at your own risk.
  • Find a Pharmacy
  • Health News
  • Medications
  • Conditions
  • RxCoupons
  • Mobile App
  • Pharmacy Solutions
  • Terms and Conditions
  • Privacy Policy
  • Contact
  • Home
    Facebook
  • Home
    Google Plus
  • Home
    Twitter
© 2020 Digital Pharmacist Inc.